Stock Quote Notification for Eli Lilly and Company

Eli Lilly and sent this email to their subscribers on June 6, 2024.

Company: Eli Lilly and Company
Ticker: LLY
Exchange: NYSE
Last Trade: $837.29
Change: 5.53
% Change: +0.66%
Volume: 2,107,512
Day's High: $846.97
Day's Low: $831.88
Previous Close: $831.76

Text-only version of this email

Eli Lilly and Company Company: Eli Lilly and Company Ticker: LLY Exchange: NYSE Last Trade: $837.29 Change: 5.53 % Change: +0.66% Volume: 2,107,512 Day's High: $846.97 Day's Low: $831.88 Previous Close: $831.76

Show all

The Latest Emails Sent By Eli Lilly and

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Weekly Summary Alert for Eli Lilly and Company

Weekly Summary Alert for Eli Lilly and Company

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer